China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2010 - 2026)

China Pharma Holdings (CPHI) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $44.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 224.77% year-over-year to $44.7 million; the trailing twelve-month figure through Jun 2026 stood at $136.7 million (up 142.57% YoY), and the FY2025 full-year result was $31.0 million, up 108.22% from the prior year.
• Liabilities and Shareholders Equity slipped to $44.7 million in Q2 2026 per CPHI's latest filing, from $45.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $45.1 million in Q1 2026 and bottomed at $13.5 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $20.1 million across 5 years, with a median of $16.2 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity dropped 21.48% in 2022, then soared 224.77% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $17.8 million in 2022, then retreated by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then surged by 108.22% to $31.0 million in 2025, then jumped by 44.23% to $44.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $44.7 million, $45.1 million, and $31.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.